Immune Activation of the Monocyte-Derived Dendritic Cells Using Patients Own Circulating Tumor Cells

New protocols for monocyte-derived dendritic cell (mMo-DC) production using automatization and circulating tumor cell lysates were introduced including a feasible in vitro assay for mMo-DC efficacy evaluation.